Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 31, 2009 (Fiscal Third Quarter)
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which develops and markets contact lenses, and CooperSurgical (CSI), which manufactures medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
All figures in thousands, except per share data.
| Metric | Three Months Ended July 31, 2009 | Nine Months Ended July 31, 2009 |
|---|---|---|
| Net Sales | $285,230 | $796,966 |
| Gross Profit | $146,395 | $437,586 |
| Gross Margin | 51.3% | 54.9% |
| Operating Income | $33,925 | $107,913 |
| Net Income | $21,908 | $70,430 |
| Diluted EPS | $0.48 | $1.55 |
| Operating Cash Flow (9mo) | $144,652 | |
| Total Debt (Short + Long Term) | $838,973 | |
| Cash and Cash Equivalents | $3,790 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2% year-over-year for both the three-month and nine-month periods. On a constant currency basis, sales grew 4%.
- Profitability: Operating income increased 9% for the quarter and 36% for the nine-month period compared to the prior year. Net income rose 23% for the quarter and 96% for the nine-month period.
- Margins: Gross margin declined to 51% from 56% in the quarter, and from 57% to 55% for the nine-month period. This compression was primarily due to restructuring costs and inventory write-offs at CooperVision.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased 10% for the quarter and 12% for the nine-month period, driven by efficiency improvements and reduced marketing spend.
- Segment Performance: CooperVision sales grew 2%, while CooperSurgical sales grew 4% for the quarter. CooperVision operating income grew 2%, while CooperSurgical operating income grew 26%.
Guidance, Outlook, and Risks
- Restructuring Initiatives: CooperVision initiated a manufacturing restructuring plan to relocate operations from Norfolk, Virginia, and Adelaide, Australia, to Puerto Rico and the UK. Total estimated costs are approximately $25 million, with $4.1 million recognized in the current quarter. A separate "Critical Activity" restructuring plan is expected to cost $3.9 million.
- Product Outlook: Management expects continued growth in silicone hydrogel and disposable lens markets. New product launches include Biofinity toric and planned Avaira toric lenses to compete in the shifting market landscape.
- Liquidity: The Company maintains $3.8 million in cash and cash equivalents with $236.8 million in available credit under its revolving line of credit. Management believes this is sufficient to fund operations, capital expenditures, and dividends for the next 12 months.
- Risks: Key risks include the global economic downturn affecting consumer spending, potential failure to realize restructuring savings, supply chain disruptions for silicone hydrogel components, and ongoing legal proceedings (securities and derivative litigation).
- Accounting Adjustments: The Company recorded out-of-period adjustments for cost of sales errors totaling $3.6 million in the current quarter, which decreased net income. Management determined these were not material to prior or current full-year results.
Investor Verification Checklist
- Restructuring Execution: Verify the timeline and cost realization of the CooperVision manufacturing relocation and the "Critical Activity" restructuring plans.
- Margin Recovery: Monitor gross margin trends to ensure the impact of restructuring costs and inventory write-offs is temporary and does not indicate structural pricing pressure.
- Legal Proceedings: Track the status of the In re The Cooper Cos., Inc., Securities Litigation and derivative lawsuits, noting the trial date set for February 17, 2010.
- Product Mix Shift: Assess the success of new silicone hydrogel toric product launches in offsetting declines in conventional lens sales.
- Debt Management: Review the Company's ability to service its debt load ($839 million total) amidst potential interest rate fluctuations and credit market volatility.